Fenfluramine: potential new label for rare type of epilepsy?
12 Feb 2020
byAudrey Abella
The amphetamine derivative fenfluramine, previously marketed as an appetite suppressant to manage obesity, delivers a different promise in a new phase III trial by showing its anti-epileptic potential in children and young adults with Dravet syndrome.